Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 271 to 285 of 292 results for diarrhea

  1. Teduglutide for treating short bowel syndrome (TA804)

    Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.

  2. Ustekinumab for treating active psoriatic arthritis (TA340)

    Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.

  3. Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

    Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.

  4. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

    Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.

  5. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  6. Bosutinib for previously treated chronic myeloid leukaemia (TA401)

    Evidence-based recommendations on bosutinib (Bosulif) for previously treated chronic myeloid leukaemia in adults.

  7. Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (DG28)

    Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy

  8. Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)

    Evidence-based recommendations on lorlatinib (Lorviqua) for untreated ALK-positive advanced non-small-cell lung cancer in adults.

  9. Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)

    This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.

  10. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

  11. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (DG18)

    Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay)

  12. Depression in adults: treatment and management (NG222)

    This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.

  13. Intrapartum care (NG235)

    This guideline covers the care of women and their babies during labour and immediately after birth. It focuses on women who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.

  14. Research recommendations

    research should focus on clinical outcomes relevant to people with chronic diarrhoea, such as severity of symptoms, including urgency....

  15. 25,000 people to benefit after NICE recommends new ulcerative colitis treatment

    New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA